Elora Therapeutics

Our patent-pending formulation is engineered to degrade the four most common plastic polymers found in human tissues—Polyethylene Terephthalate (PET), Polyethylene (PE), Polypropylene (PP), and Polystyrene (PS)—breaking them down into safe, excretable byproducts. By uniting advanced enzyme design with translational science, Elora is charting a new course in molecular medicine.

We are advancing early validation efforts on the road to clinical development. Our team brings together scientists and entrepreneurs committed to addressing synthetic burden at its biological root.

02 Science

Our lead therapeutic candidate is composed of four engineered enzyme variants optimized for broad-spectrum microplastic degradation within the human body.

Microplastics are increasingly recognized as bioactive pollutants, not inert bystanders. Once they enter the bloodstream and tissues, they interfere with cellular function, trigger oxidative stress, impair hormonal signaling, and contribute to chronic inflammation. Their presence has been linked to chronic inflammation, endocrine disruption, metabolic dysfunction, and now possibly cancer, yet no therapeutic options currently exist to address their accumulation in the human body.

At Elora, we’re developing a first-of-its-kind therapeutic: a systemically delivered enzyme composition designed to degrade microplastics in vivo. Unlike environmental enzymes, ours are optimized for human physiology, stable in serum, active at physiological pH, and capable of transforming synthetic polymers into small, excretable monomers.

Our current formulation targets four high-prevalence polymers in the human body: PET, PE, PP, and PS. In collaboration with leading academic partners, we are conducting early-stage validation studies to assess enzyme activity, stability, and biocompatibility in biologically relevant systems.

This is molecular intervention at the root cause. This is science built to address a modern, synthetic threat.

03 Team and Advisory Board

Paul Swartzendruber founded Elora Therapeutics to address one of the most overlooked threats to human health: microplastic accumulation in the body. With a background spanning early-stage product development and business, international policy, and now biotechnology commercialization, Paul brings a multidisciplinary lens to therapeutic innovation.
Prior to launching Elora, Paul served as a Foreign Service Officer with the U.S. Department of State, where he oversaw chemical and biological weapons issues. Earlier in his career, he held roles in marketing and product strategy at VRBO, led marketing at a tech startup acquired by a major media platform, and co-founded a consumer hardware company. This uncommon blend of technical curiosity, operational rigor, and public health focus laid the groundwork for Elora’s mission to develop first-in-class enzyme therapeutics for systemic microplastic degradation.
He holds degrees from The University of Texas at Austin, University of Maryland University College, and Harvard University.

Dr. Marc Deller is Co-Founder and Chief Scientific Officer (CSO) of Elora Therapeutics. He is a globally recognized leader in Structure-Based Drug Design (SBDD) and drug discovery, with over 20 years of experience across academia, biotech, and pharma. He is known for pioneering innovations in protein science, X-ray crystallography, Cryo-Electron Microscopy (Cryo-EM), and AI-driven SBDD.
Dr. Deller has held senior scientific roles at Incyte Pharmaceuticals, Stanford University, Scripps Research Institute, and Pfizer. There, he established and led automated structural biology platforms, managed multi-million-dollar research budgets, and mentored cross-functional teams in high-impact therapeutic programs involving cytokine-based receptor tyrosine kinase, cell surface receptors, antibodies, and small-molecule therapeutics.
His work has contributed to more than 6 oncology, virology, and immunology programs reaching FDA IND filings, and he has published over 60 manuscripts and 3 patents in the field of protein science and SBDD.
Marc completed his post-doctoral research at Yale University and received his PhD in Structural Biology from University of Oxford. He earned his bachelor’s degree in Biochemistry and Molecular Biology from University of Leeds.

Dr. Bryce Nicholls serves as a scientific advisor to Elora Therapeutics, contributing deep expertise in protein engineering, biocatalysis, and translational enzyme research. His guidance supports Elora’s strategy to develop safe, effective enzyme therapeutics capable of degrading microplastics in the human body.
Currently a Protein Engineering Test Engineer at Ginkgo Bioworks, Bryce brings hands-on experience advancing enzyme technologies for Fortune 500 clients. He has authored multiple peer-reviewed articles in leading journals including Nature Catalysis, Science, and Chemical Reviews, and was awarded Synlett’s “Paper of the Year” in 2022.
Bryce earned his Ph.D. in Chemistry from Princeton University, where he led the first known protein engineering campaign on a photoenzymatic reaction—work that resulted in several high-impact publications and the development of new screening methods for non-natural biocatalysts. He later completed a postdoctoral fellowship at Cornell University focused on polymer chemistry and peptide–polymer conjugation in collaboration with industry partners.
He also maintains a strong commitment to scientific education and equity, having taught college-level chemistry through the Cornell Prison Education Program and contributed to national conversations on inclusive pedagogy.

Nilima or “Nili” serves as a strategic advisor to Elora Therapeutics, contributing deep expertise in global program management, medical product development, and cross-sector alliance building. Her advisory work at Elora draws on a unique blend of strategic insight, operational rigor, and a lifelong commitment to translating science into impact. With over 25 years of experience leading high-impact operations across biotech, government, and international health sectors, Nilima plays a key role in guiding Elora’s clinical development strategy and operational planning.
She has directed end-to-end development of vaccines and therapeutics from preclinical through clinical phases, with particular experience managing complex portfolios across private biotech companies, government contractors, and CMOs. At the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DoD), she led international, cross-functional teams supporting the development and oversight of medical countermeasure portfolios—including through Naval Advanced Medical Development (NAMD). Her track record includes building consensus across agencies and organizations to deliver results under highly regulated and high-stakes conditions.
Nilima earned her Master of Science in Cellular and Microbial Biology from The Catholic University of America, where she conducted research on enzyme activity in Plasmodium falciparum. She also holds a Bachelor of Science in Biology from the College of St. Elizabeth.

Bruce Auerbach serves as a strategic advisor to Elora Therapeutics, offering guidance on therapeutic development and early-stage clinical planning. With over two decades of experience in pharmaceutical R&D, including as co-founder and president of AlphaCore Pharma, Bruce brings deep expertise in translational science, SBIR funding, and successful biotech exits.
As co-founder and president of AlphaCore Pharma, he utilized SBIRs, angel investments, and CRADA’s with the NIH to develop a biologic for the treatment of acute coronary syndromes. Following a successful Phase 1 clinical trial, AlphaCore was acquired by MedImmune, a subsidiary of AstraZeneca. Prior to starting AlphaCore, he was an Associate Research Fellow at Pfizer specializing in drug discovery and early clinical development, with a concentration in dyslipidemia and metabolic diseases.
Bruce graduated with a MS in Pathology and Comparative Medicine from the Bowman Gray School of Medicine of Wake Forest University.

04 Contact

At Elora, we are committed to bringing novel therapies to patients. Reach out to learn more.

To request information, please use the form below.

Thank you for reaching out! We’ll respond to you soon.

Elora Therapeutics, Inc.

5900 Balcones Dr, Ste 9059

Austin, Texas 78731

Privacy Policy

Terms of Use